← Back

Everest Medicines Ltd

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 1952.HK
Biotech & Genomic Medicine▲2impact 4

Moderna and Merck's cancer vaccine succeeds in Phase III trial, A-share vaccine stocks hit 20% daily limit

Moderna and Merck announced preliminary positive results from the Phase III clinical trial of their mRNA personalized cancer vaccine, intismeran autogene, igniting the A-share pharmaceutical sector. On the morning of August 20, multiple vaccine stocks including Baike Biotech, Walvax Biotechnology, CanSino Biologics, Kanghua Biologics, Laimei Pharmaceutical, and Novoprotein hit the 20% daily limit, while Hong Kong-listed CanSino Biologics and Everest Medicines surged over 50% intraday. The vaccine, combined with Keytruda, was used as adjuvant therapy in more than 1,100 high-risk melanoma patients after complete surgical resection, achieving key endpoints of recurrence-free survival and reduced risk of distant metastasis. Following the announcement, Moderna's stock price soared nearly 180%, while Merck's rose over 12%.
MRNA ▲MRK ▲300142.CS ▲300841.CS ▲1952.HK ▲688137.CG ▲+1
Biotech & Genomic Medicine ▲
红星资本局·6dRead more ▾
1952.HK▼

Everest Medicines interim revenue up 157%, Nefecon contributes nearly 80% of income

Everest Medicines disclosed its 2026 interim results, with total revenue of 1.148 billion yuan, up 157.3% year on year, and adjusted profit of 97.232 million yuan, turning from loss to profit. Sales revenue of its core product, the IgA nephropathy drug Nefecon, was 889 million yuan, contributing more than 77% of revenue, but still short of the company's previously set full-year 2026 target of 2.4 billion to 2.6 billion yuan, with the first half completing only about 37% of the lower end of the target. The company's other income came from a commercialisation services partnership with Haisen Bio, which has contributed 145 million yuan in sales revenue and 28 million yuan in profit since launching in March 2026. After the results were announced, Everest Medicines' share price fell 18.72% on the day to 23.8 Hong Kong dollars, with a total market capitalisation of 8.421 billion Hong Kong dollars.
1952.HK ▼
红星资本局·8dRead more ▾
1952.HK▲

Everest Medicines Closes Licensing Deal with Travere for Civorebrutinib

Everest Medicines has closed its exclusive licensing agreement with Travere Therapeutics for the development and commercialization of civorebrutinib, a potential best-in-class oral BTK inhibitor, in the U.S. and global markets outside Greater China and select Asian countries. Everest receives an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in milestone payments across up to five indications, plus tiered royalties ranging from high single-digit to double-digit percentages on future sales.
1952.HK ▲TVTX ▲
PR Newswire·50dRead more ▾
Biotech & Genomic Medicine▲

Everest Medicines' LEROCHOL BLA Accepted by China NMPA for Hypercholesterolemia

Everest Medicines announced that China's National Medical Products Administration accepted the Biologics License Application for LEROCHOL, a third-generation PCSK9 inhibitor, for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The application is based on global trials and a Phase 3 study in China, where LEROCHOL showed placebo-adjusted LDL-C reductions of 65.9% at week 12 and 67.0% for the mean of weeks 10 and 12, with over 95% of participants achieving dual Chinese lipid guideline targets. The drug is a once-monthly subcutaneous injection with up to three months of room-temperature stability. LEROCHOL has already been approved by the U.S. FDA and is under review by the European Medicines Agency. Everest Medicines expects potential approval in mainland China in 2027.
1952.HK ▲
Biotech & Genomic Medicine
PR Newswire·62dRead more ▾
1952.HK▲

Everest Medicines and Hainan Herui enter commercialization collaboration for budesonide enteric capsules

Everest Medicines and Hainan Herui have entered into a commercialization collaboration for Hainan Herui's budesonide enteric capsules, which were approved by China's National Medical Products Administration in December 2025. Under the agreement, Everest Medicines will handle commercialization in the Chinese mainland market and provide technical guidance and quality audits over manufacturing and supply. The collaboration aims to enhance patient access to the combined franchise of NEFECON and Hainan Herui's budesonide enteric capsules, and is subject to customary closing conditions.
1952.HK ▲
PR Newswire·64dRead more ▾
Biotech & Genomic Medicine▲

Everest Medicines signs exclusive Asia-Pacific license with Dimerix for kidney disease drug DMX-200

Everest Medicines has signed an exclusive licensing agreement with Dimerix to develop and commercialize DMX-200 across Asia-Pacific. The deal focuses on treating serious kidney diseases such as focal segmental glomerulosclerosis, an area with significant unmet medical need. DMX-200 is already in a pivotal Phase 3 trial for that condition, giving Everest access to a late-stage program that fits its existing nephrology focus and regional commercial infrastructure. The agreement expands Everest's renal pipeline, which already includes LNZ100, Nefecon, MT1013, and EVER001, reinforcing a multi-asset approach in kidney disease therapies. Everest's shares stood at HK$26.68 at the time of the announcement, down 29.6% year to date.
1952.HK ▲
Biotech & Genomic Medicine
Simply Wall St·69dRead more ▾
© 2026 MarketDXAsset